Drugs /

tadalafil

Back to Drugs List

Overview

NCI Definition [1]:
A carboline-based compound with vasodilatory activity. Tadalafil selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase- (PDE-5)-mediated degradation of cGMP, which is found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. Inhibition of cGMP degradation by tadalafil results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection.

Clinical Trials

View Clinical Trials for tadalafil

Tadalafil has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating tadalafil, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 3 are phase 2 (3 open).

Head and neck squamous cell carcinoma, colorectal carcinoma, and hepatocellular carcinoma are the most common diseases being investigated in tadalafil clinical trials [2].

Drug Details

Synonyms [2]:
tadalafil, 351, ic, (6r,12ar)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, tadalafil [chemical/ingredient], tadalafil (substance), 171596-29-5, ic 351, (6r-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, icos 351, ic351, cialis, tadalafil, 6-benzo[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, (6r,12ar)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6r,12ar)-, tadalafil (product), ic351, ic-351, tadanafil
NCIT ID [1]:
C47743
SNOMED ID [1]:
F-61DB0

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.